Delivery Order SPE2DB24D9113-SPE2DB25FEQDG
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL auto-injector units. The delivery order, awarded on August 15, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair auto-injectors valued at $1,712.22. This delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, utilizes firm fixed-price pricing and was awarded without set-aside designation. The award is issued under DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a $51,366.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, represents a specific fulfillment order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of September 5, 2025, represents a specific fulfillment under the company's larger Indefinite Delivery Contract with DLA valued at $499,999,999...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $1,712.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/ml autoinjectors, with a period of performance through October 3, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 300 mg/2 ml auto-injector units. The contract, valued at $10,273.38 with a firm fixed-price structure, was awarded on August 14, 2025, with an ultimate completion date of September 5, 2025. This delivery order was issued without a set-aside designation, and performance will take place at the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 20, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract has a ceiling value of $85,611.50 with an ultimate completion date of September 11, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $28.3K by the Defense Logistics Agency's Medical Supply Chain on August 27, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order is scheduled for completion by September 18, 2025, with no set-aside designation applied. The award represents a discrete fulfillment under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, valued at $1,712.23, was executed on August 22, 2025, with an ultimate completion date of September 15, 2025. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on a full-and-open basis within...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 300 mg/2 ml auto-injector prefilled syringes. The contract, valued at $6,848.92 with a firm fixed-price structure, was awarded on August 13, 2025, with an ultimate completion date of September 4, 2025. This delivery order carries no set-aside designation and will be performed at the company's Park...
- SPE2DB24D9113Indefinite Delivery Contract
- SPE2DB24D9113-SPE2DB25FEQDGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector units. This firm fixed-price delivery order, issued on September 8, 2025, with a completion date of September 29, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA. The IDC, valued at $499.9 million and valid through November 2026, authorizes the agency to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables for Department of Defense healthcare facilities. This award is issued without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive position as a women-owned small business in federal pharmaceutical procurement. The company has established itself as a critical supplier in the federal pharmaceutical supply chain through its SPE2DB program contract with the DLA, consistently delivering specialized medical products including auto-injectors, vaccines, and specialty medications to military health facilities nationwide. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, and this delivery order fulfills immediate medical supply requirements for federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 9/8/25 |